“…[19][20][21][22][23] As a result, numerous strategies are under development to block FXII (a). [24][25][26] These strategies are directed to completely inhibit all of its functions. As it remains unclear whether FXII-driven contact activation is completely obsolete, or whether it has physiological value (perhaps outside hemostasis), it is warranted to develop therapies with maximal selectivity.…”